Following the established corporate strategy, the Group proactively advances the development of the vaccine product pipelines, and leverages the advantages of the mRNA technology platform to accelerate the research and development of mRNA vaccine series products through on-going technological innovation. The application for clinical trial of the mRNA shingles/ herpes zoster vaccines developed by the Group has been submitted to the Center for Drug Evaluation (CDE) of National Medical Products Administration of China recently.

Following the established corporate strategy, the Group proactively advances the development of the vaccine product pipelines, and leverages the advantages of the mRNA technology platform to accelerate the research and development of mRNA vaccine series products through on-going technological innovation. The application for clinical trial of mRNA RSV (respiratory syncytial virus) vaccines has been submitted to the U.S. Food and Drug Administration (“FDA”) recently.

The clinical trial approval for the Group’s second generation of highly-effectiveabsorbed tetanus vaccine has been recently obtained from the National Medical Products Administration, which marks a new progress of the research and development of the vaccine.

The clinical trial approval for the Group’s suspension culture quadrivalent influenza vaccine (MDCK cells) with new technological route has been recently obtained from the National Medical Products Administration, which marks a new progress of the research and development of the vaccine. Currently, all influenza vaccines available on the domestic market are produced using chicken embryo technology. There have not been cell-based influenza vaccines approved for marketing. As a heavyweight key product, influenza vaccine (MDCK cells) is expected to become a new growth driver of the Group after its launch.

The 2024 Corporate Day event (the “Event”) of AIM Vaccine Co., Ltd. (“AIM Vaccine”or the “Group”) was successfully held on November 21, 2024.

The pre-application for marketing registration of the iterative serum-free rabies vaccine independently developed by the Group has been submitted to the National Medical Products Administration recently.

The application for clinical trial of the iterative-process highly-effective human diploid rabies vaccine developed by the Group has been submitted to the Center for Drug Evaluation (CDE) of National Medical Products Administration of China recently.

The application for drug marketing registration of the Group’s independently developed 13-valent pneumonia conjugate vaccine has been submitted to the National Medical Products Administration on October 31, 2024.

The board of directors of the Company (the “Board”) is pleased to announce that the clinical trial approval for the mRNA respiratory syncytial virus (RSV) vaccine developed by a controlled subsidiary of the Group, Liverna Therapeutics Inc., has been recently obtained from the National Medical Products Administration, which marks a new progress of the research and development of the vaccine.